Humacyte (HUMA) Q2 2024 earnings summary

Executive summary

• FDA review of the ATEV BLA for vascular trauma was delayed, with no revised action date, but commercial launch preparations and board expansion continue.

• ATEV met primary endpoints and showed superior functional patency over standard of care in the V007 Phase 3 trial for hemodialysis access.

• Third RMAT designation received for ATEV in advanced peripheral artery disease, highlighting broad applicability.

• Preclinical and clinical pipeline progress includes diabetes, coronary artery bypass, and pediatric heart surgery.

• The company has not generated product revenue and continues to incur significant operating losses and negative cash flows.

Financial highlights

• No revenues reported for Q2 2024 or the six months ended June 30, 2024.

• R&D expenses rose to $23.8M in Q2 2024 from $20.5M in Q2 2023, and to $45.0M for the first half of 2024 from $37.8M in 2023.

• G&A expenses decreased to $5.7M in Q2 2024 from $6.2M in Q2 2023.

• Net loss increased to $56.7M in Q2 2024 from $22.7M in Q2 2023, and to $88.6M for the first half of 2024 from $59.7M in 2023.

• Cash and equivalents were $93.6M as of June 30, 2024, up from $80.4M at year-end 2023; $43M raised in public offering and $20M from funding arrangement in H1 2024.

Outlook and guidance

• Confident in ATEV approvability for vascular trauma, pending FDA review completion; commercial launch preparations ongoing.

• Additional capital will be required within the next year to continue operations, with current liquidity insufficient to fund operations beyond one year without FDA approval and/or new financing.

• Supplemental BLA for dialysis access expected to be filed in 2025, pending trauma approval; phase 3 trial design for PAD under consideration.

• Ongoing preclinical and clinical development in additional indications, including diabetes and coronary artery bypass.